Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

SYRE

Spyre Therapeutics Inc.

Sep 20 • 04:00PM ET

30.17

Dollar change -0.23
Percentage change -0.76	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM XBI VXF IWN VTWO VHT LABU ITOT NUSC

Index	RUT	P/E	-	EPS (ttm)	-15.45	Insider Own	10.90%	Shs Outstand	50.92M	Perf Week	2.76%
Market Cap	1.54B	Forward P/E	-	EPS next Y	-3.56	Insider Trans	-0.33%	Shs Float	45.37M	Perf Month	13.55%
Income	-185.98M	PEG	-	EPS next Q	-0.83	Inst Own	92.39%	Short Float	18.65%	Perf Quarter	25.19%
Sales	0.00M	P/S	-	EPS this Y	92.59%	Inst Trans	-10.48%	Short Ratio	13.90	Perf Half Y	-24.31%
Book/sh	4.30	P/B	7.01	EPS next Y	2.13%	ROA	-54.73%	Short Interest	8.46M	Perf Year	177.81%
Cash/sh	8.37	P/C	3.61	EPS next 5Y	-	ROE	-222.71%	52W Range	8.43 - 47.97	Perf YTD	40.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	1.60%	ROI	-49.68%	52W High	-37.11%	Beta	2.93
Dividend TTM	-	Quick Ratio	19.70	Sales past 5Y	-49.91%	Gross Margin	39.53%	52W Low	257.89%	ATR (14)	1.81
Dividend Ex-Date	-	Current Ratio	19.70	EPS Y/Y TTM	79.05%	Oper. Margin	0.00%	RSI (14)	59.30	Volatility	6.43% 6.27%
Employees	30	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.11	Target Price	47.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	98.49%	Payout	-	Rel Volume	3.53	Prev Close	30.40
Sales Surprise	-100.00%	EPS Surprise	9.45%	Sales Q/Q	-100.00%	Earnings	Aug 07 AMC	Avg Volume	608.76K	Price	30.17
SMA20	7.48%	SMA50	7.87%	SMA200	3.72%	Trades		Volume	2,151,210	Change	-0.76%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-04-24	Initiated	Wedbush	Outperform	$45
Jul-16-24	Initiated	Evercore ISI	Outperform
May-02-24	Initiated	Robert W. Baird	Outperform	$50
Mar-01-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$12 → $35
Dec-20-23	Initiated	BTIG Research	Buy	$32
Dec-11-23	Initiated	Jefferies	Buy	$31
Dec-11-23	Initiated	Guggenheim	Buy	$44
May-04-20	Initiated	Piper Sandler	Overweight	$12
Mar-21-19	Initiated	JP Morgan	Overweight	$14
Sep-04-18	Downgrade	Wells Fargo	Outperform → Market Perform
Apr-24-18	Initiated	Evercore ISI	Outperform	$37
Mar-14-18	Reiterated	Needham	Buy	$8 → $12

Show Previous Ratings

Sep-10-24 04:47PM	Spyre Therapeutics to Participate in Upcoming Investor Conference (PR Newswire)
Aug-07-24 11:53PM	SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024 (InvestorPlace) -5.72%
04:05PM	Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire) -5.22%
Jun-18-24 07:30AM	Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-47 Antibody, for the Treatment of Inflammatory Bowel Disease (PR Newswire)
05:23PM	Loading…
Jun-03-24 05:23PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +5.26% -7.31%
May-29-24 08:30AM	Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference (PR Newswire)
May-15-24 07:30AM	Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors (PR Newswire)
May-09-24 10:54PM	SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +6.57%
04:02PM	Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-03-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Apr-01-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -7.27%
Mar-18-24 08:00AM	Spyre Therapeutics Announces $180 Million Private Placement (PR Newswire) -11.68%
Mar-04-24 08:50AM	Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength (Zacks) +16.96%
Mar-01-24 05:25PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +8.97%
04:05PM	Loading…
Feb-29-24 04:05PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (PR Newswire) +5.13%
Feb-26-24 07:30AM	Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference (PR Newswire)
Feb-08-24 07:30AM	Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation (PR Newswire)
Feb-06-24 09:55AM	Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher (Zacks)
Feb-05-24 07:30AM	Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors (PR Newswire)
Feb-02-24 05:30PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Dec-22-23 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +5.52% +6.22%
Dec-08-23 07:19AM	Spyre Therapeutics raises $180 million to advance anti-inflammatory drugs (BioPharma Dive)
Dec-07-23 06:20PM	Spyre Therapeutics Announces $180 Million Private Placement (PR Newswire)
Nov-28-23 08:00AM	Spyre Therapeutics to Present at Upcoming Investor Conference (PR Newswire) +20.73%
Nov-27-23 08:30AM	Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD (PR Newswire) +8.79%
Nov-22-23 05:00PM	Aeglea BioTherapeutics Announces Grants of Inducement Awards (PR Newswire) +6.26%
Nov-09-23 06:26PM	Aeglea: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-03-23 05:00PM	Aeglea BioTherapeutics Announces Grants of Inducement Awards (PR Newswire) -5.39%
08:00PM	Loading…
Oct-30-23 08:00PM	Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences (PR Newswire) +9.57%
Oct-02-23 06:02PM	Aeglea BioTherapeutics Announces Grants of Inducement Awards (PR Newswire)
Sep-14-23 05:03PM	Aeglea BioTherapeutics to Participate in Upcoming September Conference (PR Newswire) -6.63%
Sep-07-23 08:40AM	Aeglea BioTherapeutics Announces Reverse Stock Split (PR Newswire)
Sep-05-23 07:00AM	Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones (PR Newswire)
Aug-11-23 07:07AM	Aeglea: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
Jul-27-23 07:00AM	Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma (PR Newswire)
Jun-23-23 04:30PM	Aeglea BioTherapeutics Announces Grant of Inducement Awards (PR Newswire) -12.30% -5.30%
10:31AM	Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics (Zacks)
Jun-22-23 10:59AM	Aeglea BioTherapeutics Stock Surges Over 400% Today - What's Going On (Benzinga) +328.67%
08:17AM	Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics (PR Newswire)
May-13-23 08:03AM	Aeglea BioTherapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-11-23 08:15AM	Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Aeglea: Q1 Earnings Snapshot (AP Finance)
07:01AM	Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
Apr-13-23 09:44AM	Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails (Zacks) -7.37%
Apr-12-23 07:00AM	Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives (PR Newswire) -26.21%
Mar-17-23 05:30PM	Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.35%
Mar-02-23 10:15AM	Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates (PR Newswire)
Feb-12-23 07:40AM	Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) insiders placed bullish bets worth US$695k in the last 12 months (Simply Wall St.)
Jan-06-23 07:01AM	Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency (PR Newswire)
Jan-02-23 07:29AM	Here's Why Aeglea BioTherapeutics (NASDAQ:AGLE) Must Use Its Cash Wisely (Simply Wall St.)
Dec-14-22 12:00PM	Aeglea (AGLE) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Dec-02-22 04:05PM	Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +18.17% -5.90%
Nov-30-22 10:38AM	Aeglea Nosedives After Clinical Update On Investigational Candidate For Rare Metabolism Disease (Benzinga) -65.98%
07:01AM	Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer (PR Newswire)
Nov-15-22 04:25PM	Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer (PR Newswire) -5.88%
Nov-03-22 08:35AM	Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.56%
07:01AM	Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates (PR Newswire)
Oct-21-22 12:27PM	Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers (Zacks) +6.02%
12:06PM	AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition (Zacks)
Oct-19-22 04:05PM	Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment (PR Newswire)
Oct-17-22 11:57AM	NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce (Zacks)
Oct-04-22 11:05AM	FDA Puts Partial Hold On Aeglea's Rare Disorder Trial In Pediatric Patients (Benzinga)
07:01AM	Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program (PR Newswire)
Aug-29-22 04:05PM	Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 (PR Newswire) +16.74% -13.51%
Aug-27-22 09:18AM	Trade Alert: Marcio De'Souza At Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), Has Just Spent US$50k Buying A Small Number of Shares (Simply Wall St.)
Aug-25-22 11:52AM	Aeglea (AGLE) Down on Corporate Restructuring, CEO Steps Down (Zacks)
Aug-24-22 12:40PM	Aeglea Bio Feels FDA Refusal Pinch, Cuts Workforce, Shifts Pipeline Focus (Benzinga) -19.87%
08:01AM	Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring (PR Newswire)
Aug-22-22 12:28PM	Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment (Zacks) -17.15%
Aug-20-22 10:49AM	Even after rising 85% this past week, Aeglea BioTherapeutics (NASDAQ:AGLE) shareholders are still down 88% over the past three years (Simply Wall St.)
Aug-19-22 06:26AM	Read Why Aeglea BioTherapeutics Shares Are Skyrocketing Today? (Benzinga) +80.23%
Aug-18-22 04:05PM	Aeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency (PR Newswire)
Aug-04-22 08:35AM	Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.41%
07:01AM	Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates (PR Newswire)
Jul-24-22 10:41AM	Here's Why Aeglea BioTherapeutics (NASDAQ:AGLE) Must Use Its Cash Wisely (Simply Wall St.)
Jul-08-22 11:14AM	Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why (Zacks)
Jul-07-22 11:22AM	Adverum (ADVM) Completes IND Amendment for Gene Therapy Study (Zacks)
Jul-04-22 11:49AM	Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU (Zacks)
Jun-29-22 12:34PM	Graybug (GRAY) to Review Strategic Alternatives, Stock Up (Zacks) -5.22%
Jun-28-22 11:52AM	Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD (Zacks) -6.86%
10:23AM	Kezar (KZR) Doubles on Promising Kidney Disorder Study Data (Zacks)
Jun-13-22 12:01PM	Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development (Zacks)
Jun-09-22 09:56AM	Having purchased US$1.8m worth of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) stock, the recent 53% pullback is not what insiders may have expected (Simply Wall St.)
Jun-03-22 10:49AM	Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug (Zacks) -14.51%
Jun-02-22 03:26PM	Repare (RPTX) Up 20% on Deal With Roche for Solid Tumor Drug (Zacks) -51.33%
03:20PM	Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals (Zacks)
12:09PM	Apellis (APLS) Files NDA for Pegcetacoplan in Geographic Atrophy (Zacks)
11:24AM	Sanofi (SNY) Gets Breakthrough Therapy Tag for Hemophilia A Drug (Zacks)
08:59AM	Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency (PR Newswire)
Jun-01-22 02:25PM	BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug (Zacks) -5.06%
02:22PM	FDA Delays Decision on TGTX's BLA for Multiple Sclerosis Drug (Zacks)
May-31-22 11:26AM	GSK to Boost Vaccine Portfolio With Affinivax Acquisition (Zacks)
May-26-22 11:18AM	Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe (Zacks)
May-25-22 12:07PM	INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study (Zacks) +9.49%
May-23-22 11:46AM	AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate (Zacks)
11:33AM	Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata (Zacks)

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burrows Scott L	Chief Financial Officer	Sep 03 '24	Sale	28.17	18,531	522,074	116,422	Sep 05 04:04 PM
Fairmount Funds Management LLC	Director	Apr 25 '24	Option Exercise	0.00	3,639,680	0	4,018,101	Apr 25 04:55 PM

Open in Screener

ARQT

Arcutis Biotherapeutics Inc

Sep 20 • 04:00PM ET

10.15

Dollar change +0.01
Percentage change 0.10	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

ARQT Arcutis Biotherapeutics Inc daily Stock Chart

Held by: VTI IWM XBI VXF IWO IBB SCHA VTWO VHT LABU

Index	RUT	P/E	-	EPS (ttm)	-2.18	Insider Own	13.25%	Shs Outstand	116.89M	Perf Week	-4.78%
Market Cap	1.19B	Forward P/E	-	EPS next Y	-1.15	Insider Trans	-1.21%	Shs Float	101.40M	Perf Month	21.70%
Income	-198.76M	PEG	-	EPS next Q	-0.41	Inst Own	99.47%	Short Float	24.34%	Perf Quarter	19.55%
Sales	132.06M	P/S	8.98	EPS this Y	59.98%	Inst Trans	9.65%	Short Ratio	10.10	Perf Half Y	-0.29%
Book/sh	1.60	P/B	6.34	EPS next Y	24.08%	ROA	-51.93%	Short Interest	24.68M	Perf Year	72.62%
Cash/sh	3.11	P/C	3.27	EPS next 5Y	9.80%	ROE	-148.92%	52W Range	1.76 - 13.17	Perf YTD	214.24%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-48.07%	ROI	-50.55%	52W High	-22.93%	Beta	1.18
Dividend TTM	-	Quick Ratio	8.19	Sales past 5Y	303.42%	Gross Margin	92.01%	52W Low	476.70%	ATR (14)	0.73
Dividend Ex-Date	-	Current Ratio	8.46	EPS Y/Y TTM	60.54%	Oper. Margin	-136.13%	RSI (14)	49.71	Volatility	8.03% 7.26%
Employees	296	Debt/Eq	1.11	Sales Y/Y TTM	1032.90%	Profit Margin	-150.51%	Recom	1.29	Target Price	18.57
Option/Short	Yes / Yes	LT Debt/Eq	1.11	EPS Q/Q	63.33%	Payout	-	Rel Volume	1.48	Prev Close	10.14
Sales Surprise	6.08%	EPS Surprise	18.68%	Sales Q/Q	494.57%	Earnings	Aug 14 AMC	Avg Volume	2.44M	Price	10.15
SMA20	-2.59%	SMA50	2.32%	SMA200	23.91%	Trades		Volume	3,608,832	Change	0.10%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-03-24	Upgrade	Mizuho	Neutral → Buy	$4 → $8
Oct-26-23	Downgrade	Mizuho	Buy → Neutral	$57 → $4
Oct-13-23	Downgrade	Goldman	Buy → Neutral	$32 → $6
Sep-07-22	Initiated	Needham	Buy	$46
Mar-17-22	Initiated	Goldman	Buy	$45
Jun-30-21	Initiated	Mizuho	Buy	$58
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$52
Nov-09-20	Upgrade	Goldman	Neutral → Buy	$34 → $36
Oct-08-20	Initiated	Truist	Buy	$38
Feb-25-20	Initiated	Guggenheim	Buy	$36
Feb-25-20	Initiated	Goldman	Neutral	$30
Feb-25-20	Initiated	Cowen	Outperform	$55
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight	$50

Show Previous Ratings

Sep-19-24 08:00AM	Arcutis Announces Publication of ZORYVE (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology (GlobeNewswire)
Sep-06-24 01:29AM	Insider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) (GuruFocus.com)
Sep-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255 (GlobeNewswire)
12:01AM	Arcutis Biotherapeutics, Inc. (ARQT): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
05:22PM	Loading…
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-28-24 08:00AM	Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis (GlobeNewswire)
Aug-22-24 08:00AM	Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-15-24 01:15PM	Q2 2024 Arcutis Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -11.27%
Aug-14-24 09:00PM	CORRECTION Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:00PM	Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-24 10:00AM	Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know (Zacks)
Aug-02-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-01-24 04:00PM	Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024 (GlobeNewswire) -5.86%
07:35AM	Loading…
Jul-29-24 07:35AM	Arcutis Announces ZORYVE U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc. (GlobeNewswire)
07:30AM	Arcutis Launches ZORYVE (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis (GlobeNewswire)
Jul-23-24 02:57PM	7 Biotech Stocks to Keep on Your Clinical Radar (InvestorPlace)
08:00AM	Arcutis Submits Supplemental New Drug Application for ZORYVE (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over (GlobeNewswire)
Jul-22-24 08:00AM	Arcutis to Host ZORYVE (Roflumilast) Cream 0.15% FDA Approval Call With KOL (GlobeNewswire)
Jul-19-24 09:40AM	Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-17-24 09:54AM	Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why (Zacks)
Jul-10-24 01:13PM	Arcutis bags FDA approval for atopic dermatitis cream after delay (Pharmaceutical Technology)
11:23AM	FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years (Benzinga)
07:48AM	AbbVie names new R&D head; Arcutis eczema cream approved (BioPharma Dive)
Jul-09-24 04:53PM	FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age (GlobeNewswire)
08:00AM	Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis (GlobeNewswire)
Jul-06-24 08:00AM	The 7 Best Under $10 Stocks to Buy in July 2024 (InvestorPlace)
Jul-03-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.27%
Jul-02-24 07:45AM	Cheap Stocks To Buy: This Microcap Gold Stock Breaks Out (Investor's Business Daily)
09:40AM	Loading…
Jun-17-24 09:40AM	Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? (Zacks) -7.76%
Jun-14-24 09:55AM	Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 99.89%: Read This Before Placing a Bet (Zacks) -7.60%
Jun-13-24 06:00AM	Have $5-10? 7 Affordable Stocks That Are About to Breakout. (InvestorPlace) +15.31%
Jun-10-24 02:30PM	Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference (GlobeNewswire)
Jun-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference (GlobeNewswire)
Jun-03-24 08:00AM	Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-31-24 09:40AM	Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? (Zacks)
May-20-24 09:55AM	Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 101.09%: Here's is How to Trade (Zacks)
May-16-24 11:23AM	Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise (MT Newswires)
May-15-24 12:54PM	Q1 2024 Arcutis Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +13.65%
12:03PM	Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating (MT Newswires)
09:12AM	Sector Update: Health Care Stocks Rise Pre-Bell Wednesday (MT Newswires)
08:53AM	Sector Update: Health Care (MT Newswires)
08:46AM	Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $18 From $17, Maintains Buy Rating (MT Newswires)
08:19AM	Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
04:24AM	Update: Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket (MT Newswires)
03:13AM	Arcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ... (GuruFocus.com)
May-14-24 08:57PM	ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:53PM	Arcutis Biotherapeutics Q1 Loss Narrows, Revenue Increases; Shares Jump (MT Newswires)
04:00PM	Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-13-24 08:00AM	Expert Panel Review Further Validates Use of ZORYVE (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology (GlobeNewswire)
May-03-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.98%
Apr-29-24 04:00PM	Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 (GlobeNewswire) -5.24%
Apr-10-24 08:00AM	Arcutis Appoints David Topper as Chief Financial Officer (GlobeNewswire)
Apr-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.49% +10.49%
Apr-01-24 07:00AM	Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve Cream (GlobeNewswire)
Mar-28-24 08:00AM	Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-19-24 09:55AM	Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-18-24 09:55AM	Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High? (Zacks)
Mar-11-24 08:00AM	Arcutis Promotes Todd Tucker to Chief Human Resources Officer (GlobeNewswire) -9.96%
Mar-10-24 04:00PM	Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-09-24 04:00PM	New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction (GlobeNewswire)
Mar-08-24 07:33PM	Peabody Energy, Citi Trends, and More Stocks See Action From Activist Investors (Barrons.com) +7.42% -9.96%
Mar-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-24 04:00PM	Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire) -6.97%
08:00AM	Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-01-24 09:55AM	Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High? (Zacks) +14.49%
09:40AM	Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-29-24 05:00PM	Arcutis to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
11:33AM	Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 11:30PM	Arcutis Announces Pricing of $150 Million Public Offering (GlobeNewswire)
04:10PM	Arcutis Announces Proposed Public Offering (GlobeNewswire)
04:00PM	Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan (GlobeNewswire)
12:16AM	Q4 2023 Arcutis Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 08:11AM	Arcutis Biotherapeutics Inc (ARQT) Reports Significant Revenue Growth in Q4 2023 (GuruFocus.com) +9.70%
05:50AM	Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-16-24 08:00AM	Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +16.69%
Feb-06-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.32%
Feb-01-24 03:04PM	Steven Cohen's Point72 Asset Management Acquires New Stake in Arcutis Biotherapeutics Inc (GuruFocus.com) +13.12%
Jan-31-24 08:00AM	Arcutis to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 08:00AM	Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial (GlobeNewswire) +14.34%
Jan-22-24 08:00AM	ZORYVE (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States (GlobeNewswire) +8.92%
Jan-18-24 12:00PM	Arcutis Biotherapeutics, Inc. (ARQT) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
Jan-14-24 04:00AM	ZORYVE (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids (GlobeNewswire)
04:00AM	Majority of Individuals with Atopic Dermatitis Improved with Arcutis' Roflumilast Cream 0.15% According to New Data from Phase 3 Program (GlobeNewswire)
Dec-23-23 07:32PM	11 High Growth Micro-Cap Stocks to Buy (Insider Monkey)
Dec-19-23 11:48AM	Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis (Zacks)
Dec-18-23 06:02AM	Arcutis Biotherapeutics receives FDA approval for ZORYVE to treat seborrheic dermatitis (Pharmaceutical Business Review)
04:58AM	Arcutis shares jump after FDA approves drug for chronic skin condition (Investing.com)
Dec-15-23 05:19PM	UPDATE 3-US FDA approves Arcutis' drug to treat chronic skin disease (Reuters)
05:14PM	US FDA approves Arcutis' drug to treat chronic skin disease (Reuters)
05:11PM	FDA Approves Arcutis' ZORYVE (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older (GlobeNewswire)
Dec-01-23 10:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.15% +12.56%
Nov-29-23 08:00AM	FDA Accepts Arcutis' Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6 (GlobeNewswire) -6.86%
Nov-17-23 09:35AM	After Plunging -35.64% in 4 Weeks, Here's Why the Trend Might Reverse for Arcutis Biotherapeutics, Inc. (ARQT) (Zacks)
Nov-16-23 11:04PM	Polar Capital Holdings Plc Bolsters Portfolio with Arcutis Biotherapeutics Inc Stake (GuruFocus.com) -6.25%
Nov-15-23 01:26PM	3 Biotech Stocks With Key Catalysts Coming in December (InvestorPlace)
Nov-14-23 05:04PM	FMR LLC Reduces Stake in Arcutis Biotherapeutics Inc (GuruFocus.com)

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Welgus Howard G.	Director	Sep 03 '24	Sale	10.77	10,000	107,695	191,944	Sep 05 05:56 PM
Welgus Howard G.	Director	Sep 03 '24	Proposed Sale	10.77	10,000	107,695		Sep 03 01:37 PM
Burnett Patrick	See Remarks	Aug 19 '24	Sale	8.29	1,728	14,318	194,859	Aug 21 04:39 PM
Burnett Patrick	Officer	Aug 19 '24	Proposed Sale	8.29	1,728	14,318		Aug 19 05:43 PM
Matsuda Masaru	See Remarks	Aug 02 '24	Sale	9.02	5,220	47,064	183,288	Aug 05 04:37 PM
Burnett Patrick	See Remarks	Aug 02 '24	Sale	9.02	13,206	119,106	196,587	Aug 05 04:37 PM
Watanabe Todd Franklin	See Remarks	Aug 02 '24	Sale	9.02	14,487	130,648	846,263	Aug 05 04:37 PM
Welgus Howard G.	Director	Aug 01 '24	Option Exercise	1.68	6,614	11,115	186,953	Aug 05 04:37 PM
Welgus Howard G.	Director	Aug 01 '24	Sale	9.87	10,000	98,696	176,953	Aug 05 04:37 PM
Matsuda Masaru	Officer	Aug 02 '24	Proposed Sale	9.02	5,220	47,063		Aug 02 04:22 PM
Burnett Patrick	Officer	Aug 01 '24	Proposed Sale	9.14	13,026	119,105		Aug 02 04:20 PM
Watanabe Todd Franklin	Officer	Aug 02 '24	Proposed Sale	9.02	14,487	130,648		Aug 02 04:19 PM
Welgus Howard G.	Director	Aug 01 '24	Proposed Sale	9.87	10,000	98,696		Aug 01 04:45 PM
Welgus Howard G.	Director	Jul 01 '24	Option Exercise	1.68	10,000	16,806	190,339	Jul 02 07:13 PM
Welgus Howard G.	Director	Jul 01 '24	Sale	9.31	10,000	93,141	180,339	Jul 02 07:13 PM
Welgus Howard G.	Director	Jun 04 '24	Option Exercise	1.68	10,000	16,806	180,200	Jun 06 04:15 PM
Welgus Howard G.	Director	Jun 04 '24	Sale	8.01	10,000	80,092	170,200	Jun 06 04:15 PM
Burnett Patrick	See Remarks	May 30 '24	Option Exercise	0.00	23,000	0	232,793	May 31 04:50 PM
Burnett Patrick	See Remarks	May 29 '24	Sale	8.72	49,952	435,387	209,793	May 31 04:50 PM
Burnett Patrick	See Remarks	May 30 '24	Sale	8.75	23,000	201,319	209,793	May 31 04:50 PM
Matsuda Masaru	See Remark	May 28 '24	Sale	9.01	1,775	15,988	188,508	May 29 07:38 PM
Edwards Larry Todd	SVP Chief Commercial Officer	May 17 '24	Sale	8.98	7,640	68,582	140,360	May 20 05:12 PM
Moore Matthew Richard	SVP and Chief Business Officer	May 02 '24	Sale	8.74	4,681	40,902	145,505	May 03 04:29 PM
Watanabe Todd Franklin	See Remarks	May 02 '24	Sale	8.74	13,783	120,433	860,750	May 03 04:22 PM
Matsuda Masaru	See Remark	May 02 '24	Sale	8.74	5,016	43,829	185,408	May 03 04:22 PM
Burnett Patrick	See Remarks	May 02 '24	Sale	8.74	9,555	83,490	259,745	May 03 04:22 PM
Matsuda Masaru	See Remark	Mar 04 '24	Sale	11.12	3,760	41,816	190,424	Mar 06 05:14 PM
Burnett Patrick	See Remarks	Mar 04 '24	Sale	11.12	4,782	53,182	269,300	Mar 06 05:12 PM
Watanabe Todd Franklin	See Remarks	Mar 04 '24	Sale	11.12	14,903	165,739	874,533	Mar 06 05:09 PM
Moore Matthew Richard	SVP and Chief Business Officer	Mar 04 '24	Sale	11.12	3,468	38,568	146,020	Mar 06 05:08 PM
Heron Patrick J	Director	Mar 04 '24	Buy	9.50	21,052	199,994	8,785,284	Mar 06 04:28 PM
Watanabe Todd Franklin	See Remarks	Feb 28 '24	Sale	10.60	2,465	26,129	889,436	Mar 01 04:11 PM
Burnett Patrick	See Remarks	Jan 02 '24	Sale	3.54	1,325	4,692	57,032	Jan 03 05:30 PM
Watanabe Todd Franklin	See Remarks	Dec 01 '23	Option Exercise	1.68	59,525	100,038	513,682	Dec 01 08:51 PM
Matsuda Masaru	See Remark	Nov 21 '23	Sale	1.98	1,850	3,661	46,634	Nov 21 05:47 PM
Frazier Life Sciences VIII, L.	10% Owner	Oct 24 '23	Buy	2.50	80,000	200,000	8,764,232	Oct 26 04:09 PM

SYRE

Spyre Therapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc

Upgrade your FINVIZ experience